Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders.

Journal of neurovirology - 1 Apr 2013

Morgan E E, Woods S P, Letendre S L, Franklin D R, Bloss C, Goate A, Heaton R K, Collier A C, Marra C M, Gelman B B, McArthur J C, Morgello S, Simpson D M, McCutchan J A, Ellis R J, Abramson I, Gamst A, Fennema-Notestine C, Smith D M, Grant I, Vaida F, Clifford D B

Abstract excerpt

This is a cross-sectional, observational study to evaluate the hypothesis that HIV-seropositive (HIV+) apolipoprotein E4 (APOE4) carriers are at increased risk for HIV-associated neurocognitive disorders (HAND) compared to APOE4 noncarriers with HIV in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group sample. APOE genotype was determined in 466 CHARTER participants with varying disease stages...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AIDS Dementia Complex
Share to Anti-Retroviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiretroviral Therapy, Highly Active

Share to Apolipoprotein E4

Share to Asymptomatic Diseases

Share to CD4 Lymphocyte Count

Share to Gene Dosage

Share to Neuropsychological Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 23408335
DOI: 10.1007/s13365-013-0152-3
PMCID: PMC3668779

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders.PMID 23408335Read ↗

Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals.Semantic proximity Read ↗

No association between Apoε4 alleles, HIV infection, age, neuropsychological outcome, or death.Semantic proximity Read ↗

Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.Semantic proximity Read ↗

Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severitySemantic proximity Read ↗

Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study.Semantic proximity Read ↗

Association between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa.Semantic proximity Read ↗

Changing clinical phenotypes of HIV-associated neurocognitive disorders.Semantic proximity Read ↗

HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy.Semantic proximity Read ↗

Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive ReviewSemantic proximity Read ↗

Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.Semantic proximity Read ↗

Host genetic factors predisposing to HIV-associated neurocognitive disorder.Semantic proximity Read ↗

An exploratory pilot study on the involvement of APOE, HFE, C9ORF72 variants and comorbidities in neurocognitive and physical performance in a group of HIV-infected people.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.